Transgene Launches €105 Million Fundraising Initiative

Transgene, a French biotechnology firm, is launching a fundraising campaign to raise approximately €105 million. The initiative involves offering new shares to institutional investors via Private Placement and to retail investors through the PrimaryBid platform. Institut Mérieux plans to invest at least €70 million, while other shareholders, including the Dassault Group, intend to contribute a combined €10 million.

The funds will accelerate the development of Transgene's myvac® program, targeting individualized therapeutic cancer vaccines. The capital increase is earmarked for research and development, manufacturing optimization, and preparation for late-stage trials. The fundraising aims to ensure financial stability until early 2028, following a previous financing through the Current Account Advance, now being converted into equity.